Evidence map›Paper›PMID 32851421›Full record

Trial reportPsychopharmacology2020

CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.

Joelle Choueiry, Crystal M Blais, Dhrasti Shah, Dylan Smith, Derek Fisher, Vadim Illivitsky, Verner Knott

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Cholinergic modulation of sensory perception and plasticity.Neuroscience and biobehavioral reviews · 2023
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Joelle ChoueiryDepartment of Neuroscience, Faculty of Medicine, University of Ottawa, 1145 Carling Ave, Ottawa, ON, K1Z 7K4, Canada. joelle.choueiry@theroyal.ca.ORCID http://orcid.org/0000-0002-3305-1029
Crystal M BlaisInstitute of Cognitive Science, Carleton University, Ottawa, ON, Canada.
Dhrasti ShahSchool of Psychology, Faculty of Social Sciences, University of Ottawa, Ottawa, ON, Canada.
Dylan SmithDepartment of Psychiatry, The Royal Ottawa Mental Health Centre, Ottawa, ON, Canada.
Derek FisherDepartment of Psychology, Faculty of Social Sciences, Mount Saint Vincent University, Halifax, NS, Canada.
Vadim IllivitskyDepartment of Psychiatry, The Royal Ottawa Mental Health Centre, Ottawa, ON, Canada.
Verner KnottDepartment of Neuroscience, Faculty of Medicine, University of Ottawa, 1145 Carling Ave, Ottawa, ON, K1Z 7K4, Canada.
University of Ottawa · CACarleton University · CAMount Saint Vincent University · CARoyal Ottawa Mental Health Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleThe combination of CDP-choline, an α7 nicotinic acetylcholine receptor (α7 nAChR) agonist, with galantamine, a positive allosteric modulator of nAChRs, is believed to counter the fast desensitization rate of the α7 nAChRs and may be of interest for schizophrenia (SCZ) patients. Beyond the positive and negative clinical symptoms, deficits in early auditory prediction-error processes are also observed in SCZ. Regularity violations activate these mechanisms that are indexed by electroencephalography-derived mismatch negativity (MMN) event-related potentials (ERPs) in response to auditory deviance. OBJECTIVES/

methodsThis pilot study in thirty-three healthy humans assessed the effects of an optimized α7 nAChR strategy combining CDP-choline (500 mg) with galantamine (16 mg) on speech-elicited MMN amplitude and latency measures. The randomized, double-blinded, placebo-controlled, and counterbalanced design with a baseline stratification method allowed for assessment of individual response differences.

resultsIncreases in MMN generation mediated by the acute CDP-choline/galantamine treatment in individuals with low baseline MMN amplitude for frequency, intensity, duration, and vowel deviants were revealed.

conclusionsThese results, observed primarily at temporal recording sites overlying the auditory cortex, implicate α7 nAChRs in the enhancement of speech deviance detection and warrant further examination with respect to dysfunctional auditory deviance processing in individuals with SCZ.

Indexed as

Adultalpha7 Nicotinic Acetylcholine ReceptorAuditory CortexAuditory PerceptionCross-Over StudiesCytidine Diphosphate CholineDouble-Blind MethodDrug Delivery SystemsElectroencephalographyEvoked Potentials, AuditoryFemaleGalantamineHealthy VolunteersHumansMaleNootropic Agentsalpha7 Nicotinic Acetylcholine ReceptorCytidine Diphosphate CholineGalantamineNootropic AgentsCDP-cholineDeviance detectionEvent-related potentialsGalantamineMMNPositive allosteric modulatorSchizophreniaSensory memoryα7 nAChR

Identifiers

PMID32851421
OpenAlexW3080875888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.